Trials / Withdrawn
WithdrawnNCT02906605
A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer
An Open-label, Randomized, Phase 2 Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate if the anti-tumor activity of JNJ-809 combined with apalutamide is improved compared with apalutamide alone for subjects with metastatic castration-resistant prostate cancer (mCRPC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-809 | JNJ-809 (1\*10\^9) colony forming units (CFU) given as an infusion. |
| DRUG | Apalutamide | Apalutamide 240 mg orally daily. |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2018-09-01
- Completion
- 2018-09-01
- First posted
- 2016-09-20
- Last updated
- 2016-11-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02906605. Inclusion in this directory is not an endorsement.